"HemoShear: a transformational story”
LLC , launched its business in 2009 with
technology discovered by UVA professors Brett Blackman and Brian Warmhoff. HemoShear works in strategic partnerships
with pharmaceutical and biotechnology companies to help them understand human
biology, validate meaningful drug targets, and profile and select those drug
candidates that are far more likely to complete human trials successfully.
Company is growing rapidly in Charlottesville as it moves into greatly expanded
lab and office space at the former Martha Jefferson Hospital. What few Virginians know, however, is that
the Company’s breakthrough science and innovative vision are poised to
transform global drug discovery and development, leading to safer and more
effective therapies, reduced costs and vastly improved probability of success
of new drug candidates.
science combines principles of physiological blood flow and primary human cells
to accurately replicate human organ and disease biology on the bench, enabling
the study of drugs at human concentrations.
Their publications and proof-of-concept studies demonstrate that
HemoShear’s "human-relevant” systems are far more predictive of human responses
than traditional cell culture and animal testing. Hemoshear also is developing a comprehensive
Human Response Database from its studies to yield insights never before
available to the scientific community using cutting-edge bioinformatics and
has received funding from four separate divisions of the National Institutes of
Health, including the largest ever Phase II Small Business Innovation Research
award from the National Heart, Lung and Blood Institute. When HemoShear recently received an SBIR award
from the National Cancer Institute - to develop a human cell-based system that
would replicate the biology of lung and pancreatic tumors, Dr. Warmhoff
explained, "Imagine a human tumor on the laboratory bench that responds to new
therapies as if it were in the human body.
That is what our science is capable of achieving.”
is currently partnering with several major pharmaceutical and biotechnology
companies on important drug discovery and safety programs.
Speakers: Jim Powers, Chairman & CEO, Brian Wamhoff, Ph.D., Co-founder and Vice President of Research & Development, and Nikki Hastings, Ph.D, President of Operations